Resources
About Us
Home Report
Store
Minimal Residual Disease Testing Market
Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (PCR, Flow Cytometry, NGS), Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor), Sample (Blood, Bone Marrow) - Global Forecast to 2031
Report ID:MRHC - 1041385 Pages: 265 Nov-2024 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Minimal Residual Disease Testing Market is expected to reach $4.45 billion by 2031, at a CAGR of 14.6% from 2024 to 2031.
Minimal Residual Disease Testing Market Size & Forecast
The growth of the minimal residual disease testing market is driven by the growing incidence of cancer, the increasing application of MRD in hematological malignancies, the high recurrence rates of some cancers, and increasing investments and funding for MRD testing. Moreover, emerging economies, the rising adoption of personalized treatments & targeted therapies in the field of oncology, and the growing use of MRD testing in cases of solid tumors are expected to generate market growth opportunities.
Click here to: Get Free Sample Copy of this report
Minimal Residual Disease Testing Market Growth Drivers
Growing Cancer Incidence
The growing awareness regarding cancer screening and early diagnosis has led to diagnoses of cancer at earlier stages, increasing survival rates further supported by advances in treatments. Surviving cancer patients are at constant risk of relapse and cancer recurrence. These patients require regular monitoring to identify signs of relapse and start early treatment. According to the International Agency for Research on Cancer, the estimated number of new cancer cases is expected to increase to 24.5 million in 2030 from 19.2 million cases in 2020.
Investments and Funding for Minimal Residual Disease Testing
The field of minimal residual disease testing has gained traction in recent years owing to the rising cancer burden and the need to improve patient outcomes. The players operating in this market are raising funds for MRD test development and commercialization. Additionally, governments around the globe are offering grants and research funding to advance minimal residual disease testing. For instance, in February 2024, Freenome Holdings, Inc. (U.S.), a biotech company involved in the development of blood tests for early cancer detection, received an investment of $254 million to advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform. This platform is also being evaluated for minimal residual disease testing with the support of biological insights derived from the company’s multiomics platform. Similarly, in September 2023, Adela, Inc. (U.S.) received an investment of $48 million from several venture capitalists and diagnostic service providers to advance its technology platform and commercialize its first product for MRD monitoring.
Minimal Residual Disease Testing Market Trends
Emergence of Digital PCR
Digital PCR (dPCR) is one of the significant technological advancements in Minimal Residual Disease (MRD) testing. Unlike conventional PCR methods that provide quantitative results based on amplification cycles, dPCR divides a sample into thousands of individual reactions for more precise quantification of nucleic acids, which enables the detection of low levels of residual disease with improved sensitivity and accuracy for monitoring patients with blood cancers.
The implementation of dPCR in clinical practices can also be attributed to its relatively simpler workflow, which requires less hands-on time compared to other advanced techniques. Due to continuous technological advancements, dPCR is expected to become more widely adopted for MRD testing.
Single-cell Multiomics and Artificial Intelligence in Minimal Residual Disease Testing
Single-cell multiomics assays simultaneously conduct the genotypic and immunophenotypic assessment of MRD across thousands of individual cells, providing clonal insight in tandem with the immunophenotype from rare residual disease cells. These high-resolution, integrated molecular profiles provide valuable insights and information regarding the complex biology of cancer MRD, which can lead to the identification of new markers for early cancer recurrence. The application of Artificial Intelligence (AI) and advanced bioinformatics tools in MRD testing is a more recent development that has enabled the analysis of vast amounts of data generated through NGS and dPCR techniques. AI-driven algorithms can identify subtle patterns in genetic data, improving the accuracy of MRD detection and predicting patient outcomes more effectively.
The growth in MRD testing is supported by advancements in technologies enabling real-time monitoring and personalized treatment. With advances in single-cell sequencing and the integration of artificial intelligence, the next generation of MRD tests could offer deeper insights into cancer recurrence, treatment resistance mechanisms, and treatment efficacy.
Minimal Residual Disease Testing Market Opportunities
Growing Use of MRD Testing in Solid Tumors
Traditionally, MRD testing has been more established and used in blood cancers, but recent advancements and research have accelerated the application of MRD testing in solid tumors. As research on MRD continues, the potential of MRD testing in informing treatment decisions for solid tumor patients is expected to improve in the future. Moreover, diagnostic companies’ focus on launching MRD tests for solid tumors indicates the growing demand for MRD testing for solid tumors. For instance, in October 2023, Personalis, Inc. (U.S.), a provider of MRD testing services for patients and clinicians, launched NeXT Personal Dx, an MRD test for clinical use to detect MRD in lung and breast cancer.
Furthermore, MRD testing can provide oncologists with valuable information, fulfilling their need for precise and accurate data to assess treatment response and recurrence risk. The ability to detect even small amounts of residual disease after surgical interventions or therapies can lead to more personalized follow-up strategies, improving patient outcomes. With ongoing research and clinical trials, the growing acceptance and implementation of MRD testing in solid tumors is expected to create opportunities for the players operating in the market.
Minimal Residual Disease Testing Market Analysis: Key Findings
By Offering: The Assays & Reagents Segment to Dominate the Minimal Residual Disease Testing Market in 2024
Based on offering, the minimal residual disease testing market is segmented into assays & reagents, instruments, and software & services. In 2024, the assays & reagents segment is expected to account for the largest share of 76.7% of the minimal residual disease testing market. The segment’s large market share is attributed to the recurrent use of assays & reagents, increasing research & development in the field of oncology leading to the emergence of new MRD tests, market players’ focus on introducing new assays for minimal residual disease testing, and the rising adoption of MRD testing in clinical trials.
Moreover, the assays & reagent segment is projected to record the highest growth rate of 15.4% during the forecast period 2024–2031. The growth of this segment is driven by the rising cancer incidence, key players’ focus on introducing new MRD tests for different types of cancer, and growing research and development for the development of new MRD tests.
By Technology: The Flow Cytometry Segment to Dominate the Minimal Residual Disease Testing Market in 2024
Based on technology, the minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction, next-generation sequencing, and other technologies. In 2024, the flow cytometry segment is expected to account for the largest share of 42.7% of the minimal residual disease testing market. The segment’s large market share is attributed to flow cytometry technology’s ability to provide real-time, quantitative data on the number and type of cancer cells in a sample, the wide availability of flow cytometers, and the relatively lower costs of flow cytometry consumables compared to more advanced technologies such as Next-generation Sequencing (NGS).
However, the polymerase chain reaction segment is projected to record the highest CAGR of 16.6% during the forecast period. The growth of this segment is driven by PCR technology’s high specificity in targeting known genetic markers and its capacity to detect disease at the molecular level, often before clinical symptoms reappear, facilitating earlier interventions and potentially improving patient outcomes. Moreover, PCR is well-suited for detecting minimal residual disease in patients, which often requires tracking of specific mutations.
By Application: The Blood Cancers Segment to Dominate the Minimal Residual Disease Testing Market in 2024
Based on application, the minimal residual disease testing market is segmented into blood cancers and solid tumors. In 2024, the blood cancers segment is expected to account for the larger share of the minimal residual disease testing market. The segment’s large market share is attributed to the growing incidence of blood cancers, the advent of new diagnostic technologies, the rising focus on precision oncology, high investments in MRD testing for blood cancers, and the wide availability of MRD testing solutions for blood cancers.
Moreover, the blood cancers segment is projected to record the higher CAGR during the forecast period 2024-2031. The growth of this segment is driven by the growing availability of MRD tests for blood cancers, the growing focus of MRD test providers on different types of blood cancers, and the rising incidence of blood cancers.
By Sample Type: The Blood Segment to Dominate the Minimal Residual Disease Testing Market in 2024
Based on sample type, the minimal residual disease testing market is segmented into blood, bone marrow, and other sample types. In 2024, the blood segment is expected to account for the largest share of the minimal residual disease testing market. The segment’s large market share is attributed to the growing cancer incidence, the noninvasiveness of procedures used to obtain blood samples, and better patient compliance in the case of regular blood-based MRD monitoring.
Moreover, the blood segment is projected to record the highest CAGR during the forecast period 2024-2031. The growth of this segment is driven by the focus of market players on launching blood-based MRD tests, growing awareness regarding MRD testing, and the convenience of blood sample collection, leading to better patient compliance.
By Customer Type: The Pharmaceutical & Biopharmaceutical Companies Segment to Dominate the Minimal Residual Disease Testing Market in 2024
Based on customer type, the minimal residual disease testing market is segmented into hospitals, diagnostic laboratories, academic & research organizations/institutions, and pharmaceutical & biopharmaceutical companies. In 2024, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the minimal residual disease testing market. The segment’s large market share is attributed to the high adoption of MRD testing in clinical trials for oncology therapies, high investments in oncology drug development and research, and supportive initiatives by regulatory authorities to promote MRD testing in drug trials.
Moreover, the pharmaceutical & biopharmaceutical companies segment is projected to record the highest CAGR during the forecast period 2024-2031. The growth of this segment is driven by the growing adoption of MRD testing in clinical trials for oncology therapies, increasing R&D investments by pharmaceutical & biopharmaceutical companies, and the growing adoption of MRD testing to validate the efficacy of drugs.
Geographical Analysis
North America to Dominate the Minimal Residual Disease Testing Market in 2024
In 2024, North America is expected to account for the largest share of 38.8% of the minimal residual disease testing market. Furthermore, in 2024, the U.S. is expected to account for the major share of the minimal residual disease testing market in North America. North America’s large market share is attributed to the rising incidence of cancer, funding for the development of MRD tests, the presence of key market players, and the rising focus on cancer screening in the region.
However, Asia-Pacific is slated to register the highest CAGR of 15.5% during the forecast period. Asia-Pacific is becoming an increasingly active market for healthcare product manufacturers and service providers due to improving healthcare infrastructure in the region. Asia-Pacific’s growing population is the key factor driving the region’s healthcare sector. This growth is attracting investments from private and public organizations in the development of MRD testing solutions. The rising incidence of cancer, improving healthcare infrastructure, the growing focus on personalized therapies, increasing cancer screening initiatives, and the availability of funding for cancer research are driving market growth in Asia-Pacific.
Minimal Residual Disease Testing Market: Key Companies
The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted in the last 3–4 years. The key players operating in the minimal residual disease testing market are Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Natera Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Adaptive Biotechnologies Corporation (U.S.), Sysmex Corporation, (Japan), Integrated DNA Technologies, Inc. (U.S.), Twist Bioscience Corporation (U.S.), and Invivoscribe Inc. (U.S.).
Minimal Residual Disease Testing Industry Overview: Latest Developments from Key Industry Players
- In April 2024, Bio-Rad Laboratories, Inc. (U.S.) collaborated with Allegheny Health Network (U.S.) to generate clinical evidence for all cancer types using droplet digital PCR (ddPCR) technology for MRD monitoring in patients.
- In April 2023, Bio-Rad Laboratories, Inc. (U.S.) launched the QX600 Droplet Digital PCR System for MRD monitoring, expanding the company’s offerings for cancer research.
- In August 2022, Thermo Fisher Scientific, Inc. (U.S.) launched the NGS-based Myeloid MRD Assay for Minimal Residual Disease (MRD) testing. The assay can accurately and comprehensively measure MRD, improving patient outcomes.
Minimal Residual Disease Testing Market Research Summary:
|
Particulars |
Details |
|
No. of Pages |
265 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
14.6% |
|
Market Size (Value) |
$4.45 Billion by 2031 |
|
Segments Covered |
By Offering
By Technology
By Application
By Sample Type
By Customer Type
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Spain, Italy, Switzerland, Netherlands, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of APAC), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa |
|
Key Companies |
Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Natera Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Adaptive Biotechnologies Corporation (U.S.), Sysmex Corporation, (Japan), Integrated DNA Technologies, Inc. (U.S.), Twist Bioscience Corporation (U.S.), and Invivoscribe Inc. (U.S.) |
Key questions answered in the report:
The minimal residual disease testing market is expected to reach $4.45 billion in 2031.
The market is projected to grow from an estimated $1.72 billion in 2024 to $4.45 billion by 2031.
The minimal residual disease testing market analysis indicates significant growth, with the market expected to reach $4.45 billion by 2031 at a Compound Annual Growth Rate (CAGR) of 14.6% from 2024 to 2031.
The key companies operating in this market include Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Natera Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Adaptive Biotechnologies Corporation (U.S.), Sysmex Corporation, (Japan), Integrated DNA Technologies, Inc. (U.S.), Twist Bioscience Corporation (U.S.), and Invivoscribe Inc. (U.S.).
Single-cell multiomics and artificial intelligence are key trends in this market. Single-cell multiomics assays simultaneously conduct the genotypic and immunophenotypic assessment of MRD across thousands of individual cells, providing clonal insight in tandem with immunophenotypes from rare residual disease cells. These high-resolution, integrated molecular profiles provide valuable insights and information regarding the complex biology of cancer MRD, which can lead to the identification of new markers for early cancer recurrence.
By product type, the reagents & assays segment is forecasted to hold the largest market share. By application, the blood cancers segment is expected to dominate the market. By technology, the flow cytometry segment is expected to dominate the market. By sample type, the blood segment is expected to dominate the market. By customer type, the pharmaceutical & biopharmaceutical companies segment is poised to hold the dominant position in the market. By geography, North America is slated to hold the largest market share.
By region, North America is expected to hold the largest share of the minimal residual disease testing market in 2024. However, Asia-Pacific is expected to record the highest CAGR during the forecast period, driven by the rising incidence of cancer, improving healthcare infrastructure, the growing focus on personalized therapies, increasing cancer screening initiatives, and the availability of funding for cancer research.
The primary drivers for the minimal residual disease testing market include the growing incidence of cancer, the increasing application of MRD in hematological malignancies, the high recurrence rates of some cancers, and increasing investments and funding for MRD testing.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Sizing & Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Growing Incidence of Cancer
4.2.1.2. Increasing Investments & Funding for MRD Testing & Research
4.2.2. Restraints
4.2.2.1. High Costs of Minimal Residual Disease Testing
4.2.3. Opportunities
4.2.3.1. Rising Adoption of Personalized Treatments & Targeted Therapies in the Field of Oncology
4.2.3.2. Growing Use of MRD Testing in Cases of Solid Tumors
4.2.4. Challenges
4.2.4.1. Chances of False Positive/Negative Results
4.2.5. Trends
4.2.5.1. Emergence of Digital PCR
4.2.5.2. Use of Mass Spectrometry for MRD Testing
4.2.5.3. Integration of Single-cell Multiomics & Artificial Intelligence Into Minimal Residual Disease Testing
4.2.6. Factors Analysis
4.3. Regulatory Analysis
4.3.1. North America
4.3.1.1. U.S.
4.3.1.2. Canada
4.3.2. Europe
4.3.3. Asia-Pacific
4.3.3.1. China
4.3.3.2. Japan
4.3.3.3. India
4.3.4. Latin America
4.3.5. Middle East
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Buyers
4.4.2. Bargaining Power of Suppliers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Technology Evolution Roadmap
5. Minimal Residual Disease Testing Market Assessment—by Offering
5.1. Overview
5.2. Assays & Reagents
5.3. Instruments
5.4. Software & Services
6. Minimal Residual Disease Testing Market Assessment—by Technology
6.1. Overview
6.2. Flow Cytometry
6.3. Polymerase Chain Reaction
6.4. Next-generation Sequencing
6.5. Other Technologies
7. Minimal Residual Disease Testing Market Assessment—by Application
7.1. Overview
7.2. Blood Cancers
7.2.1. Lymphoma
7.2.2. Leukemia
7.2.2.1. Acute Lymphoblastic Leukemia (ALL)
7.2.2.2. Chronic Lymphocytic Leukemia (CLL)
7.2.2.3. Other Leukemias
7.2.3. Multiple Myeloma
7.2.4. Other Blood Cancers
7.3. Solid Tumors
8. Minimal Residual Disease Testing Market Assessment—by Sample Type
8.1. Overview
8.2. Blood
8.3. Bone Marrow
8.4. Other Sample Types
9. Minimal Residual Disease Testing Market Assessment—by Customer Type
9.1. Overview
9.2. Pharmaceutical & Biopharmaceutical Companies
9.3. Hospitals
9.4. Diagnostic Laboratories
9.5. Academic & Research Organizations/Institutions
10. Minimal Residual Disease Testing Market Assessment—by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Switzerland
10.3.7. Netherlands
10.3.8. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. South Korea
10.4.5. Australia
10.4.6. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis (2023)
11.5.1. Natera Inc. (U.S.)
11.5.2. Bio-Rad Laboratories, Inc. (U.S.)
11.5.3. F. Hoffmann-La Roche Ltd. (Switzerland)
11.5.4. Adaptive Biotechnologies Corporation (U.S.)
12. Company Profiles
12.1. Natera Inc.
12.2. Bio-Rad Laboratories, Inc.
12.3. F. Hoffmann-La Roche Ltd.
12.4. Adaptive Biotechnologies Corporation
12.5. Illumina, Inc.
12.6. Thermo Fisher Scientific, Inc.
12.7. Qiagen N.V.
12.8. Integrated DNA Technologies, Inc. (U.S.) (A Subsidiary of Danaher Corporation [U.S.])
12.9. Twist Bioscience Corporation
12.10. Sysmex Corporation
12.11. Invivoscribe, Inc.
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Global Estimated Number of New Cancer Cases, by Type, 2020 Vs. 2030
Table 2 Cancer Recurrence Rates, by Cancer Type
Table 3 FDA-approved Personalized Therapies for Cancer, 2019-2023
Table 4 Regulatory Authorities Governing IVD, Flow Cytometry, PCR, and NGS Products, by Country/Region
Table 5 Global Minimal Residual Disease Testing Market, by Offering, 2022-2031 (USD Million)
Table 6 Key Market Players’ Assay & Reagent Offerings
Table 7 Global Minimal Residual Disease Testing Assays & Reagents Market, by Country/Region, 2022-2031 (USD Million)
Table 8 Key Market Players’ Instrument Offerings
Table 9 Global Minimal Residual Disease Testing Instruments Market, by Country/Region, 2022-2031 (USD Million)
Table 10 Key Market Players’ Software Offerings
Table 11 Global Minimal Residual Disease Testing Software & Services Market,by Country/Region, 2022-2031 (USD Million)
Table 12 MRD Testing Technologies: Overview
Table 13 Global Minimal Residual Disease Testing Market, by Technology, 2022-2031(USD Million)
Table 14 Global Flow Cytometry-based Minimal Residual Disease Testing Market,by Country/Region, 2022-2031 (USD Million)
Table 15 Global PCR-based Minimal Residual Disease Testing Market, by Country/Region, 2022-2031 (USD Million)
Table 16 Global NGS-based Minimal Residual Disease Testing Market, by Country/Region, 2022-2031 (USD Million)
Table 17 Global Other Technologies-based Minimal Residual Disease Testing Market,by Country/Region, 2022-2031 (USD Million)
Table 18 Global Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million) 90
Table 19 Global Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 20 Global Minimal Residual Disease Testing Market for Blood Cancers, by Country/Region, 2022–2031 (USD Million)
Table 21 Estimated Number of New Lymphoma Cases, by Region, 2022 Vs. 2025 Vs. 2030 (Thousand)
Table 22 Survival Rates for Diffuse Large B-Cell Lymphoma, by Seer Stage (%)
Table 23 Survival Rates for Follicular Lymphoma, by Seer Stage (%)
Table 24 Reoccurrence Rates in Lymphoma-affected Patients, by Condition (%)
Table 25 Global Minimal Residual Disease Testing Market for Lymphoma, by Country/Region, 2022–2031 (USD Million)
Table 26 Global Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 27 Global Minimal Residual Disease Testing Market for Leukemia, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Minimal Residual Disease Testing Market for Acute Lymphoblastic Leukemia, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Minimal Residual Disease Testing Market for Chronic Lymphocytic Leukemia, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Minimal Residual Disease Testing Market for Other Leukemias, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Minimal Residual Disease Testing Market for Multiple Myeloma,by Country/Region, 2022–2031 (USD Million)
Table 32 Types of Myelodysplastic Syndromes
Table 33 Types of Myeloproliferative Neoplasms
Table 34 Global Minimal Residual Disease Testing Market for Other Blood Cancers,by Country/Region, 2022–2031 (USD Million)
Table 35 Global Estimated Number of New Cancer Cases, by Type, 2020 Vs. 2030
Table 36 Global Minimal Residual Disease Testing Market for Solid Tumors,by Country/Region, 2022–2031 (USD Million)
Table 37 Global Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 38 Global Blood-based Minimal Residual Disease Testing Market, by Country/Region, 2022–2031 (USD Million)
Table 39 Global Bone Marrow-based Minimal Residual Disease Testing Market,by Country/Region, 2022–2031 (USD Million)
Table 40 Global Other Samples-based Minimal Residual Disease Testing Market,by Country/Region, 2022–2031 (USD Million)
Table 41 Global Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 42 Global Minimal Residual Disease Testing Market for Pharmaceutical & Biopharmaceutical Companies, by Country/Region, 2022–2031 (USD Million)
Table 43 Global Minimal Residual Disease Testing Market for Hospitals, by Country/Region, 2022–2031 (USD Million)
Table 44 Global Minimal Residual Disease Testing Market for Diagnostic Laboratories,by Country/Region, 2022–2031 (USD Million)
Table 45 Global Minimal Residual Disease Testing Market for Academic & Research Organizations/Institutions, by Country/Region, 2022–2031 (USDMillion)
Table 46 Global Minimal Residual Disease Testing Market, by Country/Region, 2022–2031 (USD Million)
Table 47 North America: Minimal Residual Disease Testing Market, by Country, 2022–2031 (USD Million)
Table 48 North America: Minimal Residual Disease Testing Market, by Offering, 2022–2031 (USD Million)
Table 49 North America: Minimal Residual Disease Testing Market, by Technology,2022–2031 (USD Million)
Table 50 North America: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 51 North America: Minimal Residual Disease Testing Market for Blood Cancers,by Type, 2022–2031 (USD Million)
Table 52 North America: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 53 North America: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 54 North America: Minimal Residual Disease Testing Market, by Customer Type,2022–2031 (USD Million)
Table 55 U.S.: Estimated Number of New Cancer Cases by Type & State, 2024
Table 56 U.S.: Minimal Residual Disease Testing Market, by Offering, 2022–2031 (USD Million)
Table 57 U.S.: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 58 U.S.: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 59 U.S.: Minimal Residual Disease Testing Market for Blood Cancers, by Type,2022–2031 (USD Million)
Table 60 U.S.: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031(USD Million)
Table 61 U.S.: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 62 U.S.: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 63 Canada: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 64 Canada: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 65 Canada: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 66 Canada: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 67 Canada: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 68 Canada: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 69 Canada: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031 (USD Million)
Table 70 Europe: Minimal Residual Disease Testing Market, by Country/Region, 2022–2031 (USD Million)
Table 71 Europe: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 72 Europe: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 73 Europe: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 74 Europe: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 75 Europe: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 76 Europe: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 77 Europe: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 78 Germany: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 79 Germany: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 80 Germany: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 81 Germany: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 82 Germany: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 83 Germany: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 84 Germany: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031 (USD Million)
Table 85 U.K.: Minimal Residual Disease Testing Market, by Offering, 2022–2031 (USD Million)
Table 86 U.K.: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 87 U.K.: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 88 U.K.: Minimal Residual Disease Testing Market for Blood Cancers, by Type,2022–2031 (USD Million)
Table 89 U.K.: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031(USD Million)
Table 90 U.K.: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 91 U.K.: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 92 France: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 93 France: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 94 France: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 95 France: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 96 France: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 97 France: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 98 France: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031 (USD Million)
Table 99 Italy: Minimal Residual Disease Testing Market, by Offering, 2022–2031 (USD Million)
Table 100 Italy: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 101 Italy: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 102 Italy: Minimal Residual Disease Testing Market for Blood Cancers, by Type,2022–2031 (USD Million)
Table 103 Italy: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031(USD Million)
Table 104 Italy: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 105 Italy: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 106 Spain: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 107 Spain: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 108 Spain: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 109 Spain: Minimal Residual Disease Testing Market for Blood Cancers, by Type,2022–2031 (USD Million)
Table 110 Spain: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 111 Spain: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 112 Spain: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 113 Switzerland: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 114 Switzerland: Minimal Residual Disease Testing Market, by Technology, 2022–2031 (USD Million)
Table 115 Switzerland: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 116 Switzerland: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 117 Switzerland: Minimal Residual Disease Testing Market for Leukemia, by Type,2022–2031 (USD Million)
Table 118 Switzerland: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 119 Switzerland: Minimal Residual Disease Testing Market, by Customer Type,2022–2031 (USD Million)
Table 120 Netherlands: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 121 Netherlands: Minimal Residual Disease Testing Market, by Technology, 2022–2031 (USD Million)
Table 122 Netherlands: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 123 Netherlands: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 124 Netherlands: Minimal Residual Disease Testing Market for Leukemia, by Type,2022–2031 (USD Million)
Table 125 Netherlands: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 126 Netherlands: Minimal Residual Disease Testing Market, by Customer Type,2022–2031 (USD Million)
Table 127 Rest of Europe: Number of New Cancer Cases, by Country, 2022 Vs. 2030
Table 128 Rest of Europe: Minimal Residual Disease Testing Market, by Offering, 2022–2031 (USD Million)
Table 129 Rest of Europe: Minimal Residual Disease Testing Market, by Technology,2022–2031 (USD Million)
Table 130 Rest of Europe: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 131 Rest of Europe: Minimal Residual Disease Testing Market for Blood Cancers,by Type, 2022–2031 (USD Million)
Table 132 Rest of Europe: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 133 Rest of Europe: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 134 Rest of Europe: Minimal Residual Disease Testing Market, by Customer Type,2022–2031 (USD Million)
Table 135 Asia-Pacific: Minimal Residual Disease Testing Market, by Country/Region,2022–2031 (USD Million)
Table 136 Asia-Pacific: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 137 Asia-Pacific: Minimal Residual Disease Testing Market, by Technology, 2022–2031 (USD Million)
Table 138 Asia-Pacific: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 139 Asia-Pacific: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 140 Asia-Pacific: Minimal Residual Disease Testing Market for Leukemia, by Type,2022–2031 (USD Million)
Table 141 Asia-Pacific: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 142 Asia-Pacific: Minimal Residual Disease Testing Market, by Customer Type,2022–2031 (USD Million)
Table 143 China: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 144 China: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 145 China: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 146 China: Minimal Residual Disease Testing Market for Blood Cancers, by Type,2022–2031 (USD Million)
Table 147 China: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 148 China: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 149 China: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 150 Japan: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 151 Japan: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 152 Japan: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 153 Japan: Minimal Residual Disease Testing Market for Blood Cancers, by Type,2022–2031 (USD Million)
Table 154 Japan: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 155 Japan: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 156 Japan: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 157 India: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 158 India: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 159 India: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 160 India: Minimal Residual Disease Testing Market for Blood Cancers, by Type,2022–2031 (USD Million)
Table 161 India: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 162 India: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 163 India: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 164 South Korea: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 165 South Korea: Minimal Residual Disease Testing Market, by Technology, 2022–2031 (USD Million)
Table 166 South Korea: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 167 South Korea: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 168 South Korea: Minimal Residual Disease Testing Market for Leukemia, by Type,2022–2031 (USD Million)
Table 169 South Korea: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 170 South Korea: Minimal Residual Disease Testing Market, by Customer Type,2022–2031 (USD Million)
Table 171 Australia: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 172 Australia: Minimal Residual Disease Testing Market, by Technology, 2022–2031 (USD Million)
Table 173 Australia: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 174 Australia: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 175 Australia: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 176 Australia: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 177 Australia: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031 (USD Million)
Table 178 Rest of Asia-Pacific: Number of New Cancer Cases, by Country, 2022 Vs. 2030
Table 179 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, by Offering,2022–2031 (USD Million)
Table 180 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, by Technology, 2022–2031 (USD Million)
Table 181 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 182 Rest of Asia-Pacific: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 183 Rest of Asia-Pacific: Minimal Residual Disease Testing Market for Leukemia,by Type, 2022–2031 (USD Million)
Table 184 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 185 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031 (USD Million)
Table 186 Latin America: Minimal Residual Disease Testing Market, by Country/Region,2022–2031 (USD Million)
Table 187 Latin America: Minimal Residual Disease Testing Market, by Offering, 2022–2031 (USD Million)
Table 188 Latin America: Minimal Residual Disease Testing Market, by Technology, 2022–2031 (USD Million)
Table 189 Latin America: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 190 Latin America: Minimal Residual Disease Testing Market for Blood Cancers,by Type, 2022–2031 (USD Million)
Table 191 Latin America: Minimal Residual Disease Testing Market for Leukemia, by Type,2022–2031 (USD Million)
Table 192 Latin America: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 193 Latin America: Minimal Residual Disease Testing Market, by Customer Type,2022–2031 (USD Million)
Table 194 Brazil: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 195 Brazil: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 196 Brazil: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 197 Brazil: Minimal Residual Disease Testing Market for Blood Cancers, by Type,2022–2031 (USD Million)
Table 198 Brazil: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 199 Brazil: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 200 Brazil: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031(USD Million)
Table 201 Mexico: Minimal Residual Disease Testing Market, by Offering, 2022–2031(USD Million)
Table 202 Mexico: Minimal Residual Disease Testing Market, by Technology, 2022–2031(USD Million)
Table 203 Mexico: Minimal Residual Disease Testing Market, by Application, 2022–2031(USD Million)
Table 204 Mexico: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 205 Mexico: Minimal Residual Disease Testing Market for Leukemia, by Type, 2022–2031 (USD Million)
Table 206 Mexico: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031(USD Million)
Table 207 Mexico: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031 (USD Million)
Table 208 Rest of Latin America: Minimal Residual Disease Testing Market, by Offering,2022–2031 (USD Million)
Table 209 Rest of Latin America: Minimal Residual Disease Testing Market, by Technology, 2022–2031 (USD Million)
Table 210 Rest of Latin America: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 211 Rest of Latin America: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 212 Rest of Latin America: Minimal Residual Disease Testing Market for Leukemia,by Type, 2022–2031 (USD Million)
Table 213 Rest of Latin America: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 214 Rest of Latin America: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031 (USD Million)
Table 215 Middle East & Africa: Minimal Residual Disease Testing Market, by Offering,2022–2031 (USD Million)
Table 216 Middle East & Africa: Minimal Residual Disease Testing Market, by Technology, 2022–2031 (USD Million)
Table 217 Middle East & Africa: Minimal Residual Disease Testing Market, by Application, 2022–2031 (USD Million)
Table 218 Middle East & Africa: Minimal Residual Disease Testing Market for Blood Cancers, by Type, 2022–2031 (USD Million)
Table 219 Middle East & Africa: Minimal Residual Disease Testing Market for Leukemia,by Type, 2022–2031 (USD Million)
Table 220 Middle East & Africa: Minimal Residual Disease Testing Market, by Sample Type, 2022–2031 (USD Million)
Table 221 Middle East & Africa: Minimal Residual Disease Testing Market, by Customer Type, 2022–2031 (USD Million)
Table 222 Recent Developments, by Company, 2021-2024
List of Figures
Figure 1 Market Ecosystem
Figure 2 Research Process
Figure 3 Secondary Sources Referenced for the Study
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 7 Market Sizing & Growth Forecast Approach
Figure 8 Global Minimal Residual Disease Testing Market, by Offering, 2024 Vs. 2031(USD Million)
Figure 9 Global Minimal Residual Disease Testing Market, by Technology, 2024 Vs. 2031(USD Million)
Figure 10 Global Minimal Residual Disease Testing Market, by Application, 2024 Vs. 2031(USD Million)
Figure 11 Global Minimal Residual Disease Testing Market, by Sample Type, 2024 Vs. 2031(USD Million)
Figure 12 Global Minimal Residual Disease Testing Market, by Customer Type, 2024 Vs. 2031 (USD Million)
Figure 13 Global Minimal Residual Disease Testing Market, by Geography
Figure 14 Impact Analysis of Market Dynamics
Figure 15 USFDA Regulatory Pathways for IVD Products
Figure 16 Eu Regulatory Pathway - IVDR 2017/746
Figure 17 China: Medical Device Classification and Pre-market Requirements for MRD Testing Instruments
Figure 18 Saudi Arabia: Medical Device - Marketing Authorization Process
Figure 19 Porter’s Five Forces Analysis
Figure 20 Minimal Residual Disease Testing: Technology Evolution Roadmap
Figure 21 Global Minimal Residual Disease Testing Market, by Offering, 2024 Vs. 2031(USD Million)
Figure 22 Global Minimal Residual Disease Testing Market, by Technology, 2024 Vs. 2031(USD Million)
Figure 23 Global Minimal Residual Disease Testing Market, by Application, 2024 Vs. 2031(USD Million)
Figure 24 Global Minimal Residual Disease Testing Market, by Sample Type, 2024 Vs. 2031(USD Million)
Figure 25 Global Minimal Residual Disease Testing Market, by Customer Type, 2024 Vs. 2031 (USD Million)
Figure 26 Global Minimal Residual Disease Testing Market, by Geography, 2024 Vs. 2031(USD Million)
Figure 27 North America: Minimal Residual Disease Testing Market Snapshot
Figure 28 Europe: Minimal Residual Disease Testing Market Snapshot
Figure 29 U.K.: Number of New Cancer Cases, 2022—2040
Figure 30 France: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
Figure 31 Switzerland: Number of New Cancer Cases, 2022—2040
Figure 32 Netherlands: Number of New Cancer Cases, 2022—2040
Figure 33 Asia-Pacific: Minimal Residual Disease Testing Market Snapshot
Figure 34 South Korea: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
Figure 35 Latin America: Minimal Residual Disease Testing Market Snapshot
Figure 36 Mexico: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
Figure 37 Middle East & Africa: Number of New Cancer Cases, by Country, 2022 Vs. 2030
Figure 38 Key Growth Strategies Adopted by Leading Players, 2021-2024
Figure 39 Minimal Residual Disease Testing Market: Competitive Benchmarking, by Technology
Figure 40 Minimal Residual Disease Testing Market: Competitive Benchmarking, by Region
Figure 41 Competitive Dashboard: Minimal Residual Disease Testing Market
Figure 42 Global Minimal Residual Disease Testing Market Share Analysis of Key Players (2023)
Figure 43 Natera Inc.: Financial Overview (2023)
Figure 44 Bio-Rad Laboratories, Inc.: Financial Overview (2023)
Figure 45 F. Hoffmann-La Roche Ltd.: Financial Overview (2023)
Figure 46 Adaptive Biotechnologies Corporation.: Financial Overview (2023)
Figure 47 Illumina Inc.: Financial Overview (2023)
Figure 48 Thermo Fisher Scientific, Inc.: Financial Overview (2023)
Figure 49 Qiagen N.V.: Financial Overview (2023)
Figure 50 Danaher Corporation: Financial Overview (2023)
Figure 51 Twist Bioscience Corporation: Financial Overview (2023)
Figure 52 Sysmex Corporation: Financial Overview (2024)
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Europe DTC Laboratory Testing Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Microbiology Testing Market - Global Opportunity Analysis And Industry Forecast (2024-2030)
Published Date: Jun-2024
Genetic Testing Market - Global Opportunity Analysis And Industry Forecast (2023-2030)
Published Date: Apr-2023
